alendronate and Chronic Disease studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

Excerpt	Relevance	Reference
"To determine the effect of alendronate (ALN) and teriparatide on trabecular bone score (TBS) in patients with glucocorticoid-induced osteoporosis."	9.22	Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. ( Agnusdei, D; Alam, J; Hans, D; Kohlmeier, LA; Krohn, KD; Leib, ES; MacLaughlin, EJ; Marcus, R; Saag, KG; Simonelli, C; Taylor, KA, 2016)
"The purpose of this study was to investigate the effect of alendronate on metacarpal and lumbar bone mineral density (BMD), bone resorption, and chronic back pain in postmenopausal women with osteoporosis."	9.11	Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2004)
"The current study was undertaken to investigate the effect of alendronate on bone mineral density (BMD), bone metabolism markers, and serum bone-resorbing cytokines in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis."	9.11	Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. ( Christoforidou, A; Eliopoulos, GD; Malliaraki, N; Margioris, AN; Miliaki, M; Papadaki, HA; Pontikoglou, C; Psyllaki, M; Tsatsanis, C, 2004)
"Exercise may enhance the effect of alendronate on bone mineral density (BMD) and reduce chronic back pain in elderly women with osteoporosis."	9.11	Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2005)
"To determine the effect of alendronate (ALN) and teriparatide on trabecular bone score (TBS) in patients with glucocorticoid-induced osteoporosis."	5.22	Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. ( Agnusdei, D; Alam, J; Hans, D; Kohlmeier, LA; Krohn, KD; Leib, ES; MacLaughlin, EJ; Marcus, R; Saag, KG; Simonelli, C; Taylor, KA, 2016)
"The purpose of this study was to investigate the effect of alendronate on metacarpal and lumbar bone mineral density (BMD), bone resorption, and chronic back pain in postmenopausal women with osteoporosis."	5.11	Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2004)
"The current study was undertaken to investigate the effect of alendronate on bone mineral density (BMD), bone metabolism markers, and serum bone-resorbing cytokines in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis."	5.11	Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. ( Christoforidou, A; Eliopoulos, GD; Malliaraki, N; Margioris, AN; Miliaki, M; Papadaki, HA; Pontikoglou, C; Psyllaki, M; Tsatsanis, C, 2004)
"Exercise may enhance the effect of alendronate on bone mineral density (BMD) and reduce chronic back pain in elderly women with osteoporosis."	5.11	Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. ( Iwamoto, J; Sato, Y; Takeda, T; Uzawa, M, 2005)
"Alendronate was the most frequently implicated (six cases) and risedronate (five cases)."	1.36	[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010)
"Alendronate seems to be a promising and safe agent for treatment of CIH."	1.31	Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. ( Bereket, A; Demir, E; Ozkan, B; Topçu, M, 2000)

Research

Studies (14)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (64.29)	29.6817
2010's	5 (35.71)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Saag, KG	1
Agnusdei, D	1
Hans, D	1
Kohlmeier, LA	1
Krohn, KD	1
Leib, ES	1
MacLaughlin, EJ	1
Alam, J	1
Simonelli, C	1
Taylor, KA	1
Marcus, R	1
Cardona Tortajada, F	1
Sainz Gómez, E	1
Figuerido Garmendia, J	1
Lirón de Robles Adsuar, A	1
Kunchur, R	1
Need, A	1
Hughes, T	1
Goss, A	1
Scoletta, M	1
Arduino, PG	1
Dalmasso, P	1
Broccoletti, R	1
Mozzati, M	1
Barrier, A	1
Lescaille, G	1
Rigolet, A	1
Descroix, V	1
Goudot, P	1
Ruhin, B	1
Yurci, A	1
Kalkan, AO	1
Ozbakir, O	1
Karaman, A	1
Torun, E	1
Kula, M	1
Baskol, M	1
Gursoy, S	1
Yucesoy, M	1
Bayram, F	1
O'Ryan, FS	1
Lo, JC	1
Krasagakis, K	1
Krüger-Krasagakis, S	1
Ioannidou, D	1
Tosca, A	1
Chun, CS	1
Iwamoto, J	2
Takeda, T	2
Sato, Y	2
Uzawa, M	2
Papadaki, HA	1
Tsatsanis, C	1
Christoforidou, A	1
Malliaraki, N	1
Psyllaki, M	1
Pontikoglou, C	1
Miliaki, M	1
Margioris, AN	1
Eliopoulos, GD	1
Demir, E	1
Bereket, A	1
Ozkan, B	1
Topçu, M	1
Ciancio, SG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis[NCT00051558]	Phase 3	428 participants (Actual)	Interventional	2002-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

change from baseline at endpoint in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18 month endpoint

Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD), Female Subset

Intervention	grams per square centimeters (Least Squares Mean)
Teriparatide	0.059
Alendronate	0.028

change from baseline at endpoint in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18 month endpoint

Any Fracture, Nonvertebral Fractures, Vertebral Fractures, Clinical Vertebral Fractures, and Severity Fractures

Intervention	grams per square centimeters (Least Squares Mean)
Teriparatide	0.056
Alendronate	0.023

Clinical vertebral fracture was defined as a radiographically confirmed fracture that was associated with symptoms such as back pain. (NCT00051558)
Timeframe: 36 months

Change From Baseline in Femoral Neck Bone Mineral Density (BMD), Women and Men Combined

Intervention	participants (Number)
	Any Fracture	Nonvertebral Fracture	Vertebral Fracture	Clinical Vertebral Fracture	Nonvertebral Fragility Fracture	Severity-Radiographic Vertebral Fracture: Mild	Severity-Radiographic Vertebral Fracture: Moderate	Severity-Radiographic Vertebral Fracture: Severe
Alendronate	27	15	13	4	5	7	2	4
Teriparatide	19	16	3	0	9	1	2	0

change from baseline in bone mineral density of the femoral neck as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18, 24, 36 months, and 18 and 36 month endpoints

Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Women and Men Combined

Intervention	grams per square centimeters (Least Squares Mean)
	Change, baseline to 36 month endpoint(N=185,N=177)	Change from baseline at 36 months(N=120,N=113)	Change from baseline at 24 months(N=135,N=131)	Change, baseline to 18 month endpoint(N=185,N=176)	Change from baseline at 18 months (N=156,N=145)
Alendronate	0.017	0.021	0.015	0.014	0.017
Teriparatide	0.033	0.041	0.030	0.024	0.028

change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 24 and 36 months and Endpoint at 36 months

Change From Baseline in Total Hip Bone Mineral Density (BMD), Women and Men Combined

Intervention	grams per square centimeters (Least Squares Mean)
	Change, baseline to 36 month endpoint(N=198,N=195)	Change from baseline at 36 months (N=123, N=112)	Change from baseline at 24 months (N=136, N=131)
Alendronate	0.034	0.044	0.043
Teriparatide	0.073	0.090	0.081

change from baseline in bone mineral density of the total hip as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18, 24, 36 months, and 18 and 36 month endpoints

Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Bone-Specific Alkaline Phosphatase

Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Osteocalcin

Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Serum C-terminal Propeptide of Type 1 Procollagen

Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Serum N-terminal Propeptide of Type 1 Procollagen

Time Course of Change From Baseline in Bone Turnover Markers in Subset of Patients - Serum Type 1 Collagen Degradation Fragments

Time Course of Change From Baseline in Femoral Neck Bone Mineral Density (BMD), Women and Men Combined

Intervention	grams per square centimeters (Least Squares Mean)
	Change, baseline to 36 month endpoint(N=185,N=177)	Change from baseline at 36 months(N=120,N=113)	Change from baseline at 24 months(N=135,N=131)	Change, baseline to 18 month endpoint(N=185,N=176)	Change from baseline at 18 months (N=156,N=144)
Alendronate	0.017	0.020	0.018	0.017	0.018
Teriparatide	0.032	0.037	0.034	0.026	0.027

Intervention	percent (Mean)
	Percent change from baseline at Month 1(N=65,N=78)	Percent change from baseline at Month 6(N=66,N=76)	Percent change from baseline at Month18(N=54,N=65)	Percent change from baseline at Month36(N=44,N=49)
Alendronate	0.5	-7.2	-4.1	20.6
Teriparatide	35.0	52.3	34.4	44.7

Intervention	percent (Mean)
	Percent change from baseline at Month1(N=94,N=100)	Percent change from baseline at Month 6(N=84,N=88)	Percent change from baseline at Month18(N=77,N=77)	Percent change from baseline at Month36(N=56,N=58)
Alendronate	-5.2	-33.6	-25.0	-19.6
Teriparatide	147.1	120.0	108.9	62.1

Intervention	percent (Mean)
	Percent change from baseline at Month 1(N=66,N=78)	Percent change from baseline at Month 6(N=67,N=76)	Percent change from baseline at Month18(N=55,N=65)	Percent change from baseline at Month36(N=45,N=49)
Alendronate	-8.8	-22.3	-21.3	-15.4
Teriparatide	48.2	10.5	5.1	-1.3

Intervention	percent (Mean)
	Percent change from baseline at Month 1(N=98,N=99)	Percent change from baseline at Month 6(N=86,N=85)	Percent change from baseline at Month18(N=77,N=76)	Percent change from baseline at Month36(N=59,N=57)
Alendronate	-14.8	-43.2	-35.8	-20.2
Teriparatide	107.0	130.8	86.3	61.7

Intervention	percent (Mean)
	Percent change from baseline at Month 1(N=70,N=79)	Percent change from baseline at Month 6(N=66,N=75)	Percent change from baseline at Month18(N=64,N=71)	Percent change from baseline at Month36(N=49,N=48)
Alendronate	-38.6	-42.4	-47.5	-16.2
Teriparatide	29.0	66.8	29.1	30.7

change from baseline in bone mineral density of the femoral neck as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 12, 18, 24, and 36 months

Time Course of Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Female Subset

Intervention	grams per square centimeters (Least Squares Mean)
	Change from baseline at Month 36 (N=120,N=113)	Change from baseline at Month 24 (N=135,N=131)	Change from baseline at Month 18 (N=156,N=145)	Change from baseline at Month 12 (N=167,N=158)
Alendronate	0.021	0.015	0.017	0.012
Teriparatide	0.041	0.030	0.028	0.026

change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 3, 6, 12, and 18 months

Time Course of Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), Women and Men Combined

Intervention	grams per square centimeters (Least Squares Mean)
	Change from baseline at Month 18 (N=127,N=119)	Change from baseline at Month 12 (N=139,N=129)	Change from baseline at Month 6 (N=147,N=139)	Change from baseline at Month 3 (N=149,N=150)
Alendronate	0.027	0.024	0.015	0.012
Teriparatide	0.062	0.052	0.031	0.017

change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 3, 6, 12, 18, 24, 36 months

Time Course of Change From Baseline in Total Hip Bone Mineral Density (BMD), Women and Men Combined

Intervention	grams per square centimeters (Least Squares Mean)
	Change from baseline at Month 36 (N=123,N=112)	Change from baseline at Month 24 (N=136,N=131)	Change from baseline at Month 18 (N=156,N=148)	Change from baseline at Month 12 (N=170,N=159)	Change from baseline at Month 6 (N=178,N=173)	Change from baseline at Month 3 (N=183,N=184)
Alendronate	0.044	0.043	0.031	0.028	0.018	0.012
Teriparatide	0.090	0.081	0.066	0.054	0.034	0.019

change from baseline in bone mineral density of the total hip as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 12, 18, 24, and 36 months

Article	Year
Chronic recurrent multifocal osteomyelitis of the spine and mandible: case report and review of the literature. Pediatrics, 2004, Volume: 113, Issue:4 Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Chron	2004
Systemic medications: clinical significance in periodontics. Journal of clinical periodontology, 2002, Volume: 29 Suppl 2 Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroida	2002

Article	Year
Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:9 Topics: Alendronate; Bone Density Conservation Agents; Cancellous Bone; Chronic Disease; Double-Blind Method	2016
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2009, Volume: 67, Issue:6 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co	2009
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:12 Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agen	2011
Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clinical rheumatology, 2004, Volume: 23, Issue:5 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Back Pain; Biomarkers; Bone Density; B	2004
Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. Journal of bone and mineral metabolism, 2004, Volume: 22, Issue:6 Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Diseases, Metabolic; Chronic Disease; Femal	2004
Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate. Aging clinical and experimental research, 2005, Volume: 17, Issue:2 Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Back Pain; Bone Densit	2005

Article	Year
[Chronic mouth ulcer due to inadequate ingestion of alendronate]. Atencion primaria, 2008, Volume: 40, Issue:8 Topics: Aged; Alendronate; Chronic Disease; Female; Humans; Oral Ulcer	2008
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2010, Volume: 110, Issue:1 Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chroni	2010
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. Revue de stomatologie et de chirurgie maxillo-faciale, 2010, Volume: 111, Issue:4 Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu	2010
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Age	2012
Chronic erosive and ulcerative oral lesions caused by incorrect administration of alendronate. Journal of the American Academy of Dermatology, 2004, Volume: 50, Issue:4 Topics: Aged; Alendronate; Chronic Disease; Female; Humans; Oral Ulcer	2004
Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. Journal of pediatric endocrinology & metabolism : JPEM, 2000, Volume: 13, Issue:2 Topics: Adolescent; Alendronate; Biomarkers; Bone Remodeling; Chronic Disease; Humans; Male; Osteitis Deform	2000

alendronate and Chronic Disease